TriMas Corporation — Form 10-Q Summary
Business Context and Reporting Period
TriMas designs and manufactures products for consumer products, aerospace and defense, and industrial markets through its Packaging, Aerospace, and Specialty Products segments. This unaudited Form 10-Q covers the three and nine months ended September 30, 2022, compared with the corresponding 2021 periods.
Financial Performance and Position
| Metric | Q3 2022 | Q3 2021 | 9M 2022 | 9M 2021 |
|---|---|---|---|---|
| Net sales | $218.5 million | $222.4 million | $680.5 million | $648.1 million |
| Gross profit | $48.3 million | $58.4 million | $162.7 million | $167.8 million |
| Gross margin | 22.1% | 26.3% | 23.9% | 25.9% |
| Operating profit | $21.0 million | $30.8 million | $72.8 million | $77.5 million |
| Operating margin | 9.6% | 13.9% | 10.7% | 12.0% |
| Net income | $13.3 million | $19.6 million | $47.3 million | $44.5 million |
| Diluted EPS | $0.32 | $0.45 | $1.11 | $1.03 |
For the nine months, operating cash flow was $46.6 million, versus $77.7 million in 2021. Capital expenditures were $31.8 million, and the Company paid $64.1 million for the acquisition of Intertech, partly offset by $26.2 million of proceeds from terminating prior cross-currency swaps. Cash used in financing activities was $37.5 million, including $30.0 million of share repurchases, $5.2 million of dividends, and $2.4 million related to equity-award tax withholding.
Cash and cash equivalents were $80.3 million at September 30, 2022, compared with $140.7 million at December 31, 2021. Receivables were $142.6 million and inventories were $173.7 million, reflecting increases of $17.0 million and $21.3 million, respectively, from year-end.
Long-term debt, net, was $394.5 million, consisting primarily of $400.0 million of 4.125% senior notes due April 2029. The Company had no revolving-credit borrowings and approximately $293.9 million of availability after $6.1 million of letters of credit. Actual total net leverage was 2.00x versus a 4.00x covenant limit, and interest coverage was 13.07x versus a 3.00x minimum. The Company was in compliance with its financial covenants.
Material Changes Versus the Prior Comparable Period
- Third-quarter sales declined 1.7%, while nine-month sales increased 5.0%, primarily reflecting the Intertech, Omega, and TFI acquisitions.
- Third-quarter net income fell 32%, and operating profit fell $9.8 million, as lower Packaging demand, unfavorable mix, energy and steel inflation, labor shortages, supply-chain inefficiencies, and foreign-exchange effects more than offset acquisition contributions.
- Nine-month net income increased $2.8 million despite lower operating profit, principally because 2021 included $10.5 million of debt-financing and refinancing expenses.
- Packaging sales declined 6.0% in the third quarter as consumer customers reduced personal-care and home-care inventories. Nine-month Packaging sales increased 1.7%, but operating profit declined 12.8%.
- Aerospace third-quarter operating profit included a $4.8 million pre-tax gain on the sale of vacant land; nine-month Aerospace operating profit still declined 12.3% because of mix and operating inefficiencies.
- Specialty Products benefited from stronger industrial and North American oil-field activity, with third-quarter sales up 14.5% and nine-month sales up 23.3%.
- Foreign currency translation reduced other comprehensive income by $33.0 million for the nine months. The Company also entered new cross-currency swaps with $150.0 million of initial notional amounts.
- The Company repurchased 1.0 million shares for $30.0 million during the nine months and had $112.7 million remaining under its authorization.
Guidance, Outlook, Risks and Unusual Items
The filing does not provide specific quantitative full-year revenue or earnings guidance. Management expects continued uncertainty in consumer-product demand, aircraft production rates, industrial activity, inflation, energy costs, supply chains, labor availability, foreign exchange, and the effects of COVID-19 and geopolitical tensions.
Management expects to use pricing, sourcing, continuous-improvement initiatives, footprint actions, and potential realignment actions to offset inflation and demand volatility. It believes liquidity and covenant headroom are sufficient to fund debt service, capital expenditures, dividends, share repurchases, and other obligations for at least the next 12 months and the foreseeable future.
Notable items include the $4.8 million land-sale gain, $26.2 million of cash received from terminating prior cross-currency swaps, $4.3 million of 2022 realignment charges, and the Intertech acquisition. The Company also had 418 pending asbestos cases involving 4,774 claimants and recorded total asbestos-related liabilities of $24.0 million; management does not currently expect these matters to have a material adverse effect.
Key risks include demand declines, customer inventory destocking, inability to recover input-cost inflation, supply-chain and labor disruptions, foreign-currency and interest-rate volatility, leverage and debt covenant restrictions, acquisition integration, impairment charges, litigation, cybersecurity, geopolitical events, and additional asbestos claims.
Investor Verification Priorities
- Verify whether Packaging demand and customer inventory destocking improve, particularly in personal-care and home-care products.
- Assess whether pricing and productivity actions recover energy, steel, labor, freight, and other inflationary costs.
- Monitor operating cash flow, receivables and inventory growth, and conversion of earnings to cash.
- Review leverage, covenant headroom, interest costs, and the fair value of the 2029 senior notes.
- Evaluate the integration and contribution of Intertech, Omega, and TFI, including contingent consideration related to TFI.
- Separate recurring operating performance from the $4.8 million land-sale gain and other unusual items.
- Track aerospace recovery, Specialty Products exposure to oil-field activity, and foreign-exchange impacts.
- Review asbestos claim volumes, settlement costs, insurance availability, and changes in the recorded liability.